Department of Dermatology, Venereology and Leprosy, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Int J Dermatol. 2024 Jul;63(7):929-935. doi: 10.1111/ijd.17129. Epub 2024 Mar 28.
Our aim was to measure the effectiveness of oral isotretinoin with desloratadine compared with oral isotretinoin alone in treating moderate to severe acne at a tertiary care teaching hospital in North India. In this study, 90 patients with moderate to severe acne were enrolled to participate based on their fulfilling the inclusion criteria.
A randomized, assessor-blinded, parallel-arm study was conducted. Randomization was done using computer-generated tables to allocate treatments in a 1:1 ratio. A low-dose oral isotretinoin at a dose of 0.3 mg/kg/day with tab desloratadine at 5 mg/day was applied to the study group and compared against the same patients going without the dosage when controls were conducted. Follow-up was at 4, 8, and 12 weeks.
The primary outcome was an improved global acne grading system (GAGS) score and decreased acne lesion count.
patient satisfaction with treatment. The 90 participants were randomized and 15 participants dropped out of the study, leaving 75 participants for intention to treat analysis (n = 41, n = 30). At week 12, the GAGS score and acne lesion count between the study and control groups were comparable (P > 0.05). Pruritus reported was 9.76% in the study versus 33.33% in the control group (P = 0.018). Also, 53.66% of participants reported "excellent" treatment satisfaction in the study group versus 36.67% in the control group.
The addition of desloratadine to an isotretinoin regimen has a role in reducing disease and therapy-related pruritus in acne and leads to improved patient satisfaction.
我们的目的是在印度北部的一家三级保健教学医院评估与单独口服异维 A 酸相比,口服异维 A 酸联合地氯雷他定治疗中重度痤疮的疗效。在这项研究中,根据纳入标准,共招募了 90 例中重度痤疮患者参与研究。
这是一项随机、评估者设盲、平行对照双臂研究。采用计算机生成的表格进行随机分组,以 1:1 的比例分配治疗方案。试验组给予低剂量(0.3mg/kg/d)口服异维 A 酸联合地氯雷他定 5mg/d,对照组不给予该剂量。随访时间为 4、8 和 12 周。
主要结局为改善的全球痤疮分级系统(GAGS)评分和减少的痤疮皮损计数。次要结局为患者对治疗的满意度。90 名参与者被随机分组,其中 15 名参与者退出研究,75 名参与者进入意向治疗分析(n=41,n=30)。在 12 周时,研究组和对照组的 GAGS 评分和痤疮皮损计数无差异(P>0.05)。研究组瘙痒发生率为 9.76%,对照组为 33.33%(P=0.018)。此外,研究组 53.66%的参与者报告“非常满意”的治疗满意度,而对照组为 36.67%。
在异维 A 酸治疗方案中添加地氯雷他定可减少痤疮相关的疾病和治疗相关瘙痒,从而提高患者的满意度。